206 related articles for article (PubMed ID: 21333772)
1. Carbohydrate modified ultrafine ceramic nanoparticles for allergen immunotherapy.
Pandey RS; Sahu S; Sudheesh MS; Madan J; Kumar M; Dixit VK
Int Immunopharmacol; 2011 Aug; 11(8):925-31. PubMed ID: 21333772
[TBL] [Abstract][Full Text] [Related]
2. Intradermal immunization with ovalbumin-loaded poly-epsilon-caprolactone microparticles conferred protection in ovalbumin-sensitized allergic mice.
Roman BS; Espuelas S; Gómez S; Gamazo C; Sanz ML; Ferrer M; Irache JM
Clin Exp Allergy; 2007 Feb; 37(2):287-95. PubMed ID: 17250702
[TBL] [Abstract][Full Text] [Related]
3. Co-delivery of ovalbumin and CpG motifs into microparticles protected sensitized mice from anaphylaxis.
San Román B; Irache JM; Gómez S; Gamazo C; Espuelas S
Int Arch Allergy Immunol; 2009; 149(2):111-8. PubMed ID: 19127067
[TBL] [Abstract][Full Text] [Related]
4. Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis.
Gómez S; Gamazo C; San Roman B; Ferrer M; Sanz ML; Espuelas S; Irache JM
Eur J Pharm Biopharm; 2008 Nov; 70(3):711-7. PubMed ID: 18582571
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 4 agonists adsorbed to aluminium hydroxide adjuvant attenuate ovalbumin-specific allergic airway disease: role of MyD88 adaptor molecule and interleukin-12/interferon-gamma axis.
Bortolatto J; Borducchi E; Rodriguez D; Keller AC; Faquim-Mauro E; Bortoluci KR; Mucida D; Gomes E; Christ A; Schnyder-Candrian S; Schnyder B; Ryffel B; Russo M
Clin Exp Allergy; 2008 Oct; 38(10):1668-79. PubMed ID: 18631348
[TBL] [Abstract][Full Text] [Related]
6. Allergen-specific immunosuppression by ovalbumin fused with diphtheria toxin in mice sensitized with albumins of different origin.
Lee BK; Yoo JE; Jang YS; Kim JY; Hong CS; Ro JY
Clin Exp Allergy; 2004 Oct; 34(10):1642-8. PubMed ID: 15479282
[TBL] [Abstract][Full Text] [Related]
7. Gantrez AN nanoparticles as an adjuvant for oral immunotherapy with allergens.
Gómez S; Gamazo C; Roman BS; Ferrer M; Sanz ML; Irache JM
Vaccine; 2007 Jul; 25(29):5263-71. PubMed ID: 17576025
[TBL] [Abstract][Full Text] [Related]
8. Vaccinations with T-helper type 1 directing adjuvants have different suppressive effects on the development of allergen-induced T-helper type 2 responses.
Trujillo-Vargas CM; Mayer KD; Bickert T; Palmetshofer A; Grunewald S; Ramirez-Pineda JR; Polte T; Hansen G; Wohlleben G; Erb KJ
Clin Exp Allergy; 2005 Aug; 35(8):1003-13. PubMed ID: 16120081
[TBL] [Abstract][Full Text] [Related]
9. Effect of sublingual administration with a native or denatured protein allergen and adjuvant CpG oligodeoxynucleotides or cholera toxin on systemic T(H)2 immune responses and mucosal immunity in mice.
Huang CF; Wang CC; Wu TC; Chu CH; Peng HJ
Ann Allergy Asthma Immunol; 2007 Nov; 99(5):443-52. PubMed ID: 18051215
[TBL] [Abstract][Full Text] [Related]
10. Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery.
Gordon S; Saupe A; McBurney W; Rades T; Hook S
J Pharm Pharmacol; 2008 Dec; 60(12):1591-600. PubMed ID: 19000363
[TBL] [Abstract][Full Text] [Related]
11. A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne.
Gómez S; Gamazo C; San Roman B; Grau A; Espuelas S; Ferrer M; Sanz ML; Irache JM
J Immunol Methods; 2009 Aug; 348(1-2):1-8. PubMed ID: 19545572
[TBL] [Abstract][Full Text] [Related]
12. Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles?
Slütter B; Bal SM; Que I; Kaijzel E; Löwik C; Bouwstra J; Jiskoot W
Mol Pharm; 2010 Dec; 7(6):2207-15. PubMed ID: 21043518
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination.
Slütter B; Plapied L; Fievez V; Sande MA; des Rieux A; Schneider YJ; Van Riet E; Jiskoot W; Préat V
J Control Release; 2009 Sep; 138(2):113-21. PubMed ID: 19445980
[TBL] [Abstract][Full Text] [Related]
14. Immunological adjuvant effect of Boswellia serrata (BOS 2000) on specific antibody and cellular response to ovalbumin in mice.
Gupta A; Khajuria A; Singh J; Singh S; Suri KA; Qazi GN
Int Immunopharmacol; 2011 Aug; 11(8):968-75. PubMed ID: 21371582
[TBL] [Abstract][Full Text] [Related]
15. Quillaja saponin can modulate ovalbumin-induced IgE allergic responses through regulation of Th1/Th2 balance in a murine model.
Katayama S; Mine Y
J Agric Food Chem; 2006 May; 54(9):3271-6. PubMed ID: 16637684
[TBL] [Abstract][Full Text] [Related]
16. Comparison between ovalbumin and ovalbumin peptide 323-339 responses in allergic mice: humoral and cellular aspects.
Sun LZ; Elsayed S; Aasen TB; Van Do T; Aardal NP; Florvaag E; Vaali K
Scand J Immunol; 2010 May; 71(5):329-35. PubMed ID: 20500683
[TBL] [Abstract][Full Text] [Related]
17. Mesoporous silica nanoparticles act as a self-adjuvant for ovalbumin model antigen in mice.
Mahony D; Cavallaro AS; Stahr F; Mahony TJ; Qiao SZ; Mitter N
Small; 2013 Sep; 9(18):3138-46. PubMed ID: 23625779
[TBL] [Abstract][Full Text] [Related]
18. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination.
Verheul RJ; Slütter B; Bal SM; Bouwstra JA; Jiskoot W; Hennink WE
J Control Release; 2011 Nov; 156(1):46-52. PubMed ID: 21784113
[TBL] [Abstract][Full Text] [Related]
19. Immune effector cells induced by complete Freund's adjuvant exert an inhibitory effect on antigen-specific type 2 T helper responses.
Chuang YH; Chiang BL; Chou CC; Hsieh KH
Clin Exp Allergy; 1997 Mar; 27(3):315-24. PubMed ID: 9088658
[TBL] [Abstract][Full Text] [Related]
20. Bioadhesive capacity and immunoadjuvant properties of thiamine-coated nanoparticles.
Salman HH; Gamazo C; Agüeros M; Irache JM
Vaccine; 2007 Nov; 25(48):8123-32. PubMed ID: 18029067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
